scholarly journals ID3026 Current use and clinical studies of stem cells therapy for osteoarthritis in Viet Nam

2017 ◽  
Vol 4 (S) ◽  
pp. 36
Author(s):  
Tung Dang-Xuan Tran
Keyword(s):  
Rheumatoid Arthritis ◽  
Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Viet Nam ◽  
Medical Problems ◽  
Mesenchymal Stem Cell Therapy ◽  
Advanced Therapies ◽  
Stem Cells Therapy

Mesenchymal Stem Cell Therapy (MSC) is one of the newest and most advanced therapies in Regenerative and Integrative Medicine for a variety of medical problems that are not easily treated with traditional conventional allopathic medical approaches. There is an abundance of clinical experience by numerous physicians, patients and researchers proving consistently that mesenchymal stem cell-MSC therapy can be extremely helpful in Osteoarthritis and Rheumatoid Arthritis. In Viet Nam we have several researches in stem cells clinical application in OA

Should Mesenchymal Stem Cell Therapy be used in the treatment of COVID-19?

2020 ◽  
Vol 54 ◽  
Author(s):  
Namnama P. Villarta-De Dios ◽  
Evelyn S. Osio-Salido
Keyword(s):  
Stem Cells ◽  
Randomized Controlled Trial ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Standard Treatment ◽  
Controlled Trial ◽  
Mesenchymal Stem Cell Therapy ◽  
Randomized Controlled

KEY FINDINGSThere is some short-term benefit from the use of mesenchymal stem cell therapy for severe COVID-19 in a lowquality, small randomized controlled trial (RCT). Further studies, ideally with good quality RCTs, are needed toconfirm benefit and safety.• Mesenchymal stem cells (MSCs) are non-hematopoietic adult stem cells that are able to self-renew anddifferentiate into various cells of any cell lineage. MSCs have the ability to migrate (homing) to damaged tissuefor repair and regeneration, as well as signal other cells to help in tissue repair. It can effect cellular differentiation,consequently shifting the immune system from Th1 to Th2 responses.1,2• A recent review showed improved disease-associated parameters in experimental acute respiratory distresssyndrome (ARDS).3• We found three studies (one case report, one prospective cohort, and one small randomized controlled trial)reporting the effects of MSC on COVID-19. Based on low-quality evidence, it appeared that human umbilicalcord blood-derived MSC, given after failure to improve with standard treatment, had beneficial effects in termsof earlier onset of clinical improvement among individuals with severe or critical COVID-19. However, 28-dayclinical improvement and mortality were not significantly different compared to standard treatment. There wasno reported adverse reaction.• There are 52 registered and ongoing clinical trials to investigate the efficacy and safety of mesenchymal stemcells as treatment for COVID-19.• Mesenchymal stem cell therapy is not included in any of the existing guidelines for the treatment of COVID-19.

Mesenchymal Stem Cell Therapy for Nonmusculoskeletal Diseases: Emerging Applications

2009 ◽  
Vol 18 (9) ◽  
pp. 1013-1028 ◽  
Author(s):  
Tom K. Kuo ◽  
Jennifer H. Ho ◽  
Oscar K. Lee
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Musculoskeletal Diseases ◽  
Cartilage Regeneration ◽  
Building Blocks ◽  
Differentiation Potential ◽  
Mesenchymal Stem Cell Therapy

Mesenchymal stem cells are stem/progenitor cells originated from the mesoderm and can different into multiple cell types of the musculoskeletal system. The vast differentiation potential and the relative ease for culture expansion have established mesenchymal stem cells as the building blocks in cell therapy and tissue engineering applications for a variety of musculoskeletal diseases, including repair of fractures and bone defects, cartilage regeneration, treatment of osteonecrosis of the femoral head, and correction of genetic diseases such as osteogenesis imperfect. However, research in the past decade has revealed differentiation potentials of mesenchymal stem cells beyond lineages of the mesoderm, suggesting broader applications than originally perceived. In this article, we review the recent developments in mesenchymal stem cell research with respect to their emerging properties and applications in nonmusculoskeletal diseases.

scholarly journals Will Mesenchymal Stem Cell Therapy Be Effective In COVID-19?

2021 ◽  
Vol 11 (6) ◽  
pp. 281-285
Author(s):  
Srinivas Kalai ◽  
M Senthil ◽  
R Sambath Kumar ◽  
R Kameshwaran
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Immune System ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Umbilical Cord ◽  
Stem Cell Therapy ◽  
Human Umbilical Cord ◽  
Cytokine Storm ◽  
Mesenchymal Stem Cell Therapy

Background: The World Health Organization (WHO) reports that the outbreak of the deadly virus had been noted almost in all the countries worldwide. Newly no standard therapies are available to combat the situation and this remains the major challenge for healthcare professionals to provide effective treatment against the life-threatening condition. A potential regenerative medicine method using the infusion of stem cells for the treatment of lung disorders has been reported. This review attempted to explore the immunomodulatory characteristics of Mesenchymal Stem Cells (MSCs) and how these properties make them beneficial for the treatment of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) patients. Objectives: To study the effect of Mesenchymal Stem Cell therapy in treating COVID-19. Methodology: A literature search was conducted to identify recent research relating to the review's goal of analyzing the relevance of stem cells in battling SARS-CoV-2. Results: The MSCs settle in the lungs intravenously to enhance the pulmonary microenvironment, minimize immune system over-activation, and encourage regeneration of damaged lung tissues. Its therapeutic properties like immune response inhibition play a major role in combating viruses. The avoidance of cytokine storm is the most important stage in COVID-19 therapy. Their potent immunomodulatory properties have positive effects in avoiding or attenuating the cytokine storm and assisting in the regeneration of injured lung tissues/other organs. Conclusion: Intravenous human Umbilical Cord-Mesenchymal Stem Cell therapy (hUC-MSC) transplantation is a safe and effective technique that may be used as a restoration and prioritized therapeutic option for treating severe COVID-19. Keywords: Covid-19, human Umbilical Cord-Mesenchymal Stem Cell therapy (huc-msc), Immune system.

Application of Bone Marrow–Derived Mesenchymal Stem Cells for Muscle Healing After Contusion Injury in Mice

2020 ◽  
Vol 48 (5) ◽  
pp. 1226-1235 ◽  
Author(s):  
Chih-Hao Chiu ◽  
Tsan-Hsuan Chang ◽  
Shih-Sheng Chang ◽  
Gwo-Jyh Chang ◽  
Alvin Chao-Yu Chen ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mesenchymal Stem Cell Therapy ◽  
Contusion Injury ◽  
Fast Twitch

Background: Skeletal muscle injuries are very common in sports medicine. Conventional therapies have limited clinical efficacy. New treatment methods should be developed to allow athletes to return to play with better function. Purpose: To evaluate the in vitro differentiation potential of bone marrow–derived mesenchymal stem cells and the in vivo histologic and physiologic effects of mesenchymal stem cell therapy on muscle healing after contusion injury. Study Design: Controlled laboratory study. Methods: Bone marrow cells were flushed from both femurs of 5-week-old C57BL/6 mice to establish immortalized mesenchymal stem cell lines. A total of 36 mice aged 8 to 10 weeks were used to develop a muscle contusion model and were divided into 6 groups (6 mice/group) on the basis of the different dosages of IM2 cells to be injected (0, 1.25 × 105, and 2.5 × 105 cells with/without F-127 in 100 μL of phosphate-buffered saline). Histological analysis of muscle regeneration was performed, and the fast-twitch and tetanus strength of the muscle contractions was measured 28 days after muscle contusion injury, after injections of different doses of mesenchymal stem cells with or without the F-127 scaffold beginning 14 days after contusion injury. Results: The mesenchymal stem cell–treated muscles exhibited numerous regenerating myofibers. All the groups treated with mesenchymal stem cells (1.25 × 105 cells, 2.5 × 105 cells, 1.25 × 105 cells plus F-127, and 2.5 × 105 cells plus F-127) exhibited a significantly higher number of regenerating myofibers (mean ± SD: 111.6 ± 14.77, 133.4 ± 21.44, 221.89 ± 32.65, and 241.5 ± 25.95, respectively) as compared with the control group and the control with F-127 (69 ± 18.79 and 63.2 ± 18.98). The physiologic evaluation of fast-twitch and tetanus strength did not reveal differences between the age-matched uninjured group and the groups treated with various doses of mesenchymal stem cells 28 days after contusion. Significant differences were found between the control group and the groups treated with various doses of mesenchymal stem cells after muscle contusion. Conclusion: Mesenchymal stem cell therapy increased the number of regenerating myofibers and improved fast-twitch and tetanus muscle strength in a mouse model of muscle contusion. However, the rapid decay of transplanted mesenchymal stem cells suggests a paracrine effect of this action. Treatment with mesenchymal stem cells at various doses combined with the F-127 scaffold is a potential therapy for a muscle contusion. Clinical Relevance: Mesenchymal stem cell therapy has an effect on sports medicine because of its effects on myofiber regeneration and muscle strength after contusion injury.

scholarly journals Mesenchymal stem cell treatment for refractory pediatric rheumatic diseases: A single center case series

2020 ◽  
Author(s):  
Stephen Chee-Yung Wong ◽  
Leah C Medrano ◽  
Alice D Hoftman ◽  
Olcay Y Jones ◽  
Deborah K McCurdy
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Pediatric Rheumatology ◽  
Case Series ◽  
Infusion Therapy ◽  
Mesenchymal Stem Cell Transplantation ◽  
Mesenchymal Stem Cell Therapy

Abstract Background:Pediatric rheumatic disease treatment has seen a surge in innovative therapies including numerous biologic medications that show great potential. Yet, many children with advanced disease are not able to reach remission on available treatment. Mesenchymal stem cells have immunomodulatory properties, and transplantation of these stem cells have been used to successfully treat immunologic conditions like graft-versus-host disease. Mesenchymal stem cell research in adult lupus has been encouraging, but there is a lack of studies in pediatric rheumatology. This retrospective case series will highlight three children with refractory autoimmune disease who received mesenchymal stem cell therapy and review the potential benefits and risks of this emerging treatment modality.Case Presentation:Three children with established diagnoses of systemic lupus erythematosus, mixed connective tissue disease and juvenile idiopathic arthritis were under the care of pediatric rheumatology at a large, tertiary-care, teaching institution for many years. Multiple non-biologic and biologic disease-modifying anti-rheumatic drugs failed to significantly decrease disease activity, and as a result, the families chose to undergo mesenchymal stem cell therapy. After transplantation, all children improved and were able to taper off conventional immunosuppressive drugs. No serious adverse events occurred. Conclusion:The three cases presented in this study reflect comparable beneficial outcomes and minimal risks published in adult studies. Mesenchymal stem cell transplantation is a promising adjunctive treatment option that necessitates further research and development of standardized infusion therapy protocols.

scholarly journals A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal stem cell therapy

2020 ◽  
Vol 24 (6) ◽  
Author(s):  
David Nugraha ◽  
Nabila Ananda Kloping ◽  
Resti Yudhawati ◽  
Azham Purwandhono ◽  
Hanik Badriyah Hidayati
Keyword(s):  
Stem Cells ◽  
Acute Respiratory Distress Syndrome ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Mesenchymal Stem Cell Therapy ◽  
A Current

Indonesia has been fighting the COVID-19 pandemic since the beginning of March 2020, and it doesn’t look that the situation is getting better any soon. Besides the country’s current strategies to minimize the rising mortality rate, a novel therapeutic intervention is required. After a thorough search in several databases, we found stem cells to be a likely candidate. Regardless of the general use of stem cells, studies showed positive results regarding the efficacy of using these in lung injuries. Especially, mesenchymal stem cells (MSCs) are known for their easy accessibility and their diverse mechanisms of action, including MSCs immunomodulatory antiviral effect, and its ability to improve lung function. Moreover, some researches perceived these components to be applicable in COVID-19 patients with end stage acute respiratory distress syndrome (ARDS). While randomized clinical trials are still in progress, many case reports show MSCs to be an advantageous alternative to suppress the cytokine storm and help regulate the immune system. This review summarizes the common functions of MSCs and highlights its therapeutic assets to fully tackle this global pandemic. Key word: Mesenchymal Stem Cells; Cell Therapy; COVID-19; SARS-CoV-2; ARDS Abbreviations: COVID-19 – Coronavirus Disease; MSC – Mesenchymal Stem Cell; ARDS – Acute Respiratory Distress Syndrome Citation: Nugraha D, Kloping NA, Yudhawati R, Purwandhono A, Hidayati HB. A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal stem cell therapy. Anaesth. pain intensive care 2020;24(6):--- Received: , Reviewed: , Revised: , Accepted:

Sign in / Sign up

Export Citation Format

Share Document